Validation and integration of ‘omic information for personalized medicine

David de Graaf, President and CEO, Selventa

Selventa develops systems diagnostic tests for personalized medicine in disease areas such as autoimmune disorders, oncology, and infectious disease. The company analyzes molecular patient data to identify key disease-driving mechanisms and accelerates the development process to clarify therapeutic and diagnostic decisions for patient stratification. Come learn about the challenges of developing, validating, and integrating diagnostic assays for collecting complex molecular information (including genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medial records) in order to provide novel insights for patient stratification.

selventa 4.21.11Dr. David de Graaf, Ph.D., President and Chief Executive Officer, joined Selventa in 2010 to define the company’s scientific strategy, direction and general operations. Additionally, he is responsible for developing key partnerships that will enhance the company’s significance. Previously, Dr. de Graaf served as the Vice President of Biotherapeutics and Integrative Biology at Boehringer-Ingelheim, where he built a successful portfolio of clinical candidates, initiated key collaborations as well as managed scientific leadership and site operations. He also held roles with increasing responsibilities at Pfizer, AstraZeneca and the Whitehead/MIT Center for Genome Research with a focus on bringing innovative systems biology approaches to the early pipeline.  In 2012, he was selected as one of PharmaVOICE  Magazine’s “100 Most Inspiring People in the Life Sciences.”

Time & Location: 123 Snell Library, 3:30pm, February 6